Full Professor of Biomedical Engineering - McGill University

Faculty of Medicine and Health Sciences & Faculty of Dental Medicine and Oral Health Sciences

Canada Research Chair Tier-1 in Regenerative Medicine and Nanomedicine

Fellow of the Royal Society of Canada-Academy of Science

Fellow of the Canadian Academy of Health Sciences

Fellow of the Canadian Academy of Engineering

Guggenheim Fellow in Biomedical Sciences

Editor-in-Chief ‘Materials’ MDPI

Editor-in-Chief ‘Exploration of Biomat-X’ Exploration Publisher

Director of Graduate Program- Biological and biomedical Engineering

Associate Member of the department of Bioengineering and the department of Anatomy and Cell Biology

Dr. Maryam Tabrizian is a Professor in the Department of Biomedical Engineering and a Tier 1 Canada Research Chair in Nanomedicine and Regenerative Medicine and Internationally recognized for her pioneering contributions to biomaterials and nanobiotechnology, she leads an interdisciplinary research program at the interface of materials science, biology, and medicine. Her work focuses on the design of multifunctional biomaterials, smart nanocarriers and lab-on-a-chip devices for tissue regeneration and targeted therapies, particularly for diabetes and cancer.

Dr. Tabrizian has published extensively in high-impact journals and delivered numerous invited lectures worldwide. She has trained and mentored over 180 highly qualified personnel, fostering the next generation of scientists and innovators in biomedical engineering. A Fellow of the Royal Society of Canada, Canadian Academy of Health Sciences and the Canadian Academy of Engineering, she has received multiple national and international awards recognizing her leadership and innovation in translational biomaterials research.

Through her scientific vision and collaborative approach, Dr. Tabrizian continues to advance cutting-edge strategies for improving human health by bridging fundamental science and clinical applications. Her work exemplifies the transformative potential of nanomedicine in shaping the future of personalized regenerative therapies.